Provider Briefing: Mannitol/Sorbitol Irrigation Remains on Allocation
The ongoing shortage of sterile fluids and irrigation solutions continues to challenge surgical teams across the United States. Mannitol/Sorbitol (2.7% Sorbitol / 0.54% Mannitol) irrigation solution — a nonelectrolytic irrigant essential for monopolar transurethral and hysteroscopic procedures — remains on allocation from its sole U.S. manufacturer, ICU Medical, as of early 2026.
This briefing provides an overview of the shortage timeline, clinical implications, alternative strategies, and resources to help your practice and patients navigate the current supply environment.
Shortage Timeline
Understanding how we got here helps frame the current situation:
- Pre-2024: The sterile fluid and irrigation solution market had been experiencing periodic supply disruptions since approximately 2018, driven by limited manufacturing capacity, aging production facilities, and the high cost of maintaining sterile manufacturing environments. ICU Medical was already the sole manufacturer of the Sorbitol-Mannitol combination product.
- September 2024: Hurricane Helene caused catastrophic flooding at Baxter International's North Cove manufacturing facility in Marion, North Carolina. This single facility produced approximately 60% of U.S. IV fluids and irrigation solutions. Production halted entirely.
- October–December 2024: Baxter began restarting production lines, targeting 50% capacity by mid-November. The FDA authorized emergency measures including expiration date extensions for 50+ IV and irrigation product codes (up to 12 additional months) and temporary importation of Canadian-manufactured products. ICU Medical placed multiple products, including Sorbitol-Mannitol irrigation, on allocation.
- 2025: Baxter achieved substantial recovery at North Cove, and by May 2025 issued a final recovery update. However, the cascade effects continued to strain ICU Medical's production. ASHP maintained irrigation solutions on their current shortage list throughout 2025.
- Early 2026: Supply has improved but has not fully normalized. ICU Medical's allocation persists. Spot shortages continue to vary by region and facility.
Prescribing and Procedural Implications
For urologists, gynecologists, and surgical teams who rely on Mannitol/Sorbitol irrigation for monopolar transurethral and hysteroscopic procedures, the ongoing allocation creates several clinical considerations:
Procedure Planning
- Verify irrigation solution availability with your facility pharmacy before scheduling elective procedures that require nonelectrolytic irrigants
- Prioritize urgent and emergent cases when supply is constrained — communicate with your OR scheduling team about case prioritization
- Consider batching elective TURP cases to optimize use of available irrigation supply
Equipment Considerations
- If your facility has bipolar resectoscope capability, the shortage is largely mitigated — normal saline can be used safely with bipolar instruments
- For facilities without bipolar equipment, this may be an appropriate time to discuss capital equipment investment with administration, given the ongoing fragility of the nonelectrolytic irrigant supply chain
Patient Communication
- Patients scheduled for TURP and similar procedures should be informed about potential delays related to irrigation solution supply
- When discussing alternatives, frame the conversation around equipment compatibility and safety data rather than implying inferior care
- Direct patients to reliable information sources — our patient-facing guide is available at Mannitol/Sorbitol shortage update for patients
Current Availability Picture
ICU Medical (Otsuka ICU Medical LLC) remains the sole U.S. manufacturer of the Sorbitol-Mannitol combination irrigation product. Key supply details:
- Product: Sorbitol 2.7% / Mannitol 0.54% Irrigation Solution, 3,000 mL flexible bags
- NDC transition: ICU Medical has been transitioning NDC codes from "0409" to "0990" labeler codes — both may be in the market simultaneously
- Allocation status: Product remains on allocation. Order quantities are limited based on historical purchasing patterns
- Distribution: Available through standard hospital supply channels (McKesson, Cardinal Health, etc.) subject to allocation limits
For real-time availability tracking across facilities in your area, Medfinder for Providers can help identify current inventory levels.
Cost and Access Considerations
Mannitol/Sorbitol irrigation is billed as a surgical supply, typically bundled into facility fees:
- Standard pricing: Approximately $61 for 12,000 mL (four 3,000 mL bags), or ~$15–$20 per bag
- Shortage-related pricing: Some distributors have applied premium pricing or surcharges during periods of constrained supply
- Insurance coverage: Typically covered under Medicare Part A (inpatient), Part B (outpatient surgical), and commercial insurance as part of the facility surgical fee. No separate prior authorization is generally required.
- Patient financial impact: Patients rarely see this as a separate line item. However, if the shortage causes a procedure to be rescheduled at a different facility (e.g., hospital vs. ASC), out-of-pocket costs may differ based on insurance network and facility type.
Tools and Resources for Providers
Alternative Irrigation Solutions: Clinical Comparison
When Mannitol/Sorbitol is unavailable, the following alternatives should be evaluated based on available surgical equipment and patient risk factors:
Glycine 1.5%
- Compatibility: Monopolar instruments
- Key considerations: Higher incidence of neurological symptoms (4.8x relative risk vs. Mannitol 3% per published data). Risk of transient visual disturbances including blindness due to glycine's inhibitory neurotransmitter activity. Monitor closely in longer procedures with expected high-volume absorption.
- Availability: Multiple manufacturers; generally more available than Sorbitol-Mannitol
Normal Saline (0.9% NaCl)
- Compatibility: Bipolar instruments only
- Key considerations: Eliminates risk of dilutional hyponatremia and TURP syndrome. Safest metabolic profile. Requires bipolar resectoscope capital investment if not already available.
- Availability: Widely available, though also subject to intermittent shortages post-Hurricane Helene
Sterile Water for Irrigation
- Compatibility: Monopolar instruments
- Key considerations: Severely hypotonic — significant risk of intravascular hemolysis with absorption. Reserve for short procedures where absorption risk is minimal.
- Availability: Intermittently available; also on ASHP shortage list
5% Dextrose in Water (D5W)
- Compatibility: Monopolar instruments
- Key considerations: Nonelectrolytic but risk of hyperglycemia with absorption. Limited evidence base for urologic irrigation compared to other options. Caution in diabetic patients.
- Availability: Subject to the broader IV fluid shortage
For detailed patient-facing information on alternatives: Alternatives to Mannitol/Sorbitol.
Looking Ahead
The Mannitol/Sorbitol shortage highlights the fragility of the U.S. sterile fluid manufacturing infrastructure. With a single manufacturer for this combination product and only a small number of companies producing sterile irrigation solutions overall, the system has minimal resilience against disruption.
Trends to watch:
- Bipolar technology adoption: The shortage is accelerating the shift toward bipolar resectoscopes and saline irrigation across institutions
- Manufacturing diversification: FDA and industry stakeholders have discussed incentives for new manufacturers to enter the sterile fluid market
- Supply chain transparency: Hospital systems are investing in better inventory tracking and allocation management tools
Final Thoughts
The Mannitol/Sorbitol shortage requires proactive planning, clear patient communication, and clinical flexibility. By verifying supply before scheduling, evaluating equipment alternatives, and leveraging tools like Medfinder for Providers, your practice can continue to deliver excellent surgical care despite ongoing supply constraints.
Related provider resources:
%2C%20Color%3DOriginal.png)
